Brief: Hyundai Bioscience Says Co's COVID-19 Oral Drug Solved Niclosamide's Inhibitory Concentration Problem
08/12/2020 13:29
Dec 8 (Reuters) - Hyundai Bioscience Co Ltd 048410.KQ :
* HYUNDAI BIOSCIENCE CO LTD - CO'S COVID-19 ORAL DRUG SOLVED
NICLOSAMIDE'S INHIBITORY CONCENTRATION PROBLEM
* HYUNDAI BIOSCIENCE CO LTD - EARLY JANUARY 2021, WILL TAKE
CP-COV03 TO EFFICACY TESTING AGAINST COVID-19 WITH KOZRI OF
JEONBUK NATIONAL UNIVERSITY
* HYUNDAI BIOSCIENCE CO LTD - AFTER EFFICACY TESTING,
HYUNDAI
BIOSCIENCE PLANS TO GO FOR PHASE 2 CLINICAL TRIALS AND THEN
APPLY FOR EUA
Source text for Eikon: ID:nPn5BQLtSa
Further company coverage: 048410.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyundai Bioscience Co
See all newsBrief: Hyundai Bioscience Announces Successful Result From Preclinical Study Of Niclosamide-Based Oral Anticancer Drug
S.Korean vaccine firm SK Bioscience sees shares soar 30% on debut (updated)
Vaccine developer SK Bioscience to raise $1.3 bln in S.Korea's largest IPO since 2017 (updated)
Brief: Hyundai Bioscience Develops Injection Drug For Potential Treatment Of Severe Cases Of COVID-19
Brief: Hyundai Bioscience Says Co's COVID-19 Oral Drug Solved Niclosamide's Inhibitory Concentration Problem